KICK-IN GOAL LINKED TO WORST OF WITH EARLY REDEMPTION - ROCHE GS/NOVARTIS N/ALCON AG Share Price

Certificat

KNCLDU

CH1229769182

Market Closed - Swiss Exchange 16:20:00 24/06/2024 BST
99.75 CHF +0.15% Intraday chart for KICK-IN GOAL LINKED TO WORST OF WITH EARLY REDEMPTION - ROCHE GS/NOVARTIS N/ALCON AG
3 months+2.94%
6 months+2.78%

Static data

Product typeOther Certificates
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer UBS
KNCLDU
ISINCH1229769182
Date issued 23/11/2022
Maturity 25/11/2024 (142 Days)
Parity 0.31 : 1
Emission price 100 CHF
Emission volume N/A
Settlement both
Currency CHF

Technical Indicators

Highest since issue 100.5 CHF
Lowest since issue 91.9 CHF
Spread 10 CHF
Spread %1.00%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
243.3 CHF
Average target price
276.6 CHF
Spread / Average Target
+13.70%
Consensus
  1. Stock Market
  2. Certificates
  3. KNCLDU Certificat